688506 百利天恒
已收盘 06-04 15:00:01
资讯
新帖
简况
依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组
财中社 · 19:52
依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组
百利天恒：注射用BL-M08D1获临床试验批准
南方财经网 · 18:54
百利天恒：注射用BL-M08D1获临床试验批准
公募FOF年内新发规模超千亿元；谢治宇、葛兰调仓百利天恒
每日经济新闻 · 17:02
公募FOF年内新发规模超千亿元；谢治宇、葛兰调仓百利天恒
百利天恒（688506）披露以集中竞价交易方式首次回购公司股份的公告，6月3日股价下跌0.08%
证券之星 · 06-03 17:43
百利天恒（688506）披露以集中竞价交易方式首次回购公司股份的公告，6月3日股价下跌0.08%
百利天恒(688506.SH)拟1亿元至2亿元回购股份
智通财经 · 06-01
百利天恒(688506.SH)拟1亿元至2亿元回购股份
百利天恒跌10.66% 华泰证券喊买入后股价屡跌
中金财经 · 06-01
百利天恒跌10.66% 华泰证券喊买入后股价屡跌
5月29日百利天恒涨8.64%，中欧医疗健康混合A基金重仓该股
证券之星 · 05-29
5月29日百利天恒涨8.64%，中欧医疗健康混合A基金重仓该股
百利天恒涨8.64%，开源证券一个月前给出“买入”评级
证券之星 · 05-29
百利天恒涨8.64%，开源证券一个月前给出“买入”评级
百利天恒跌6.83% 招商证券在历史大顶发研报强烈推荐
中金财经 · 05-28
百利天恒跌6.83% 招商证券在历史大顶发研报强烈推荐
东吴证券：给予百利天恒买入评级
证券之星 · 05-25
东吴证券：给予百利天恒买入评级
每周股票复盘：百利天恒（688506）2025年净亏损10.54亿元，营收降56.72%
证券之星 · 05-24
每周股票复盘：百利天恒（688506）2025年净亏损10.54亿元，营收降56.72%
百利天恒跌4% 招商证券在其历史大顶发研报强烈推荐
中金财经 · 05-22
百利天恒跌4% 招商证券在其历史大顶发研报强烈推荐
百利天恒（688506）发布2025年度持续督导跟踪报告，5月21日股价上涨1.13%
证券之星 · 05-21
百利天恒（688506）发布2025年度持续督导跟踪报告，5月21日股价上涨1.13%
百利天恒（688506）披露2025年年度股东会决议公告，5月19日股价下跌2.15%
证券之星 · 05-19
百利天恒（688506）披露2025年年度股东会决议公告，5月19日股价下跌2.15%
百利天恒(688506.SH)：SI-B036双特异性抗体注射液获批在晚期实体瘤中开展临床试验
智通财经 · 05-14
百利天恒(688506.SH)：SI-B036双特异性抗体注射液获批在晚期实体瘤中开展临床试验
百利天恒（688506）披露2025年年度股东会会议资料，5月13日股价上涨0.57%
证券之星 · 05-13
百利天恒（688506）披露2025年年度股东会会议资料，5月13日股价上涨0.57%
恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议
21世纪经济报道 · 05-13
恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议
百利天恒董秘空缺超三个月 董事长暂代职
财中社 · 05-12
百利天恒董秘空缺超三个月 董事长暂代职
百利天恒最新公告：注射用T-Bren用于一线HER2阳性乳腺癌III期临床试验完成首例受试者入组
证券之星 · 05-12
百利天恒最新公告：注射用T-Bren用于一线HER2阳性乳腺癌III期临床试验完成首例受试者入组
百利天恒：iza-bren（EGFR×HER3双抗ADC）获临床试验批准
南方财经网 · 05-12
百利天恒：iza-bren（EGFR×HER3双抗ADC）获临床试验批准
暂无数据
公司概况
公司名称：
四川百利天恒药业股份有限公司
所属行业：
医药制造业
上市日期：
2023-01-06
主营业务：
四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是知识产权收入、化药制剂、中成药制剂。
发行价格：
24.70
{"stockData":{"symbol":"688506","market":"SH","secType":"STK","nameCN":"百利天恒","latestPrice":212.9,"timestamp":1780556401000,"preClose":212.13,"halted":0,"volume":2081569,"delay":0,"changeRate":0.0036,"floatShares":413000000,"shares":413000000,"eps":-3.1408,"marketStatus":"已收盘","change":0.77,"latestTime":"06-04 15:00:01","open":214.31,"high":222.49,"low":211.5,"amount":449000000,"amplitude":0.0518,"askPrice":212.9,"askSize":21,"bidPrice":212.89,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-3.1408,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780623000000},"marketStatusCode":5,"adr":0,"adjPreClose":212.13,"symbolType":"stock_kcb","openAndCloseTimeList":[[1780536600000,1780543800000],[1780549200000,1780556400000]],"highLimit":233.34,"lowLimit":190.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":412873817,"isCdr":false,"pbRate":15.58,"roa":"--","roe":"--","epsLYR":-2.61,"committee":-0.090909,"marketValue":87901000000,"turnoverRate":0.005,"status":0,"afterMarket":{"amount":0,"volume":0,"close":212.9,"buyVolume":0,"sellVolume":0,"time":1780558438866,"indexStatus":"已收盘 06-04 15:30:00","preClose":212.13},"hkstockBrief":{"symbol":"02615","market":"HK","secType":"STK","nameCN":"百利天恒","latestPrice":0,"timestamp":1780560000000,"preClose":0,"halted":7,"volume":0,"delay":0,"premium":"-100.00"},"floatMarketCap":87901000000},"requestUrl":"/m/hq/s/688506/tweets","defaultTab":"tweets","newsList":[{"id":"2640197152","title":"依托成熟毒素平台 百利天恒BL-M05D1胃癌III期试验完成首例入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2640197152","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640197152?lang=zh_cn&edition=full","pubTime":"2026-06-04 19:52","pubTimestamp":1780573920,"startTime":"0","endTime":"0","summary":"6月4日，百利天恒（688506）发布公告，公司自主研发的创新生物药注射用BL-M05D1（Claudin18.2ADC）用于在既往经一线治疗的Claudin18.2阳性晚期胃癌或胃食管结合部腺癌的III期临床试验已完成首例受试者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760581427.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02615","BL","LU1815336091.USD","BK0239","688506","91194","BK4134","LU0757428866.USD","BK4023","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640154692","title":"百利天恒：注射用BL-M08D1获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2640154692","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640154692?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:54","pubTimestamp":1780570440,"startTime":"0","endTime":"0","summary":"南财智讯6月4日电，百利天恒公告，百利天恒（简称）收到国家药品监督管理局正式批准签发的《药物临床试验批准通知书》。公司自主研发的创新生物药注射用BL-M08D1（ADC）联合用药的临床试验获得批准，适应症为弥漫大B细胞淋巴瘤。该药物与iza-bren出自同一技术平台，共享同一“连接子+毒素”平台。公司将按规定积极推进研发项目，并及时履行后续信息披露义务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760550358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK4023","91194","LU0757428866.USD","688506","BL","LU1815336091.USD","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640115566","title":"公募FOF年内新发规模超千亿元；谢治宇、葛兰调仓百利天恒","url":"https://stock-news.laohu8.com/highlight/detail?id=2640115566","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640115566?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:02","pubTimestamp":1780563760,"startTime":"0","endTime":"0","summary":"天赐良基日报第889期一、今日基金新闻速览1、公募FOF年内新发规模超千亿元公开数据显示，按认购起始日计算，截至6月3日，今年以来新发FOF产品91只，其中80只产品（份额合并计算）已经结募并公布认购情况，有效认购金额合计达到1049.07亿元。2、科技主题基金业绩现分化Wind数据显示，截至6月1日，名字中带“科技”的主动权益类基金中，今年以来回报率最高的基金业绩接近80%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606043760472889.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760472889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","91194","02615","FOF","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640908454","title":"百利天恒（688506）披露以集中竞价交易方式首次回购公司股份的公告，6月3日股价下跌0.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640908454","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640908454?lang=zh_cn&edition=full","pubTime":"2026-06-03 17:43","pubTimestamp":1780479806,"startTime":"0","endTime":"0","summary":"截至2026年6月3日收盘，百利天恒报收于212.13元，较前一交易日下跌0.08%，最新总市值为875.83亿元。该股当日开盘211.98元，最高214.98元，最低207.5元，成交额达3.48亿元，换手率为0.4%。近日，四川百利天恒药业股份有限公司发布《关于以集中竞价交易方式首次回购公司股份的公告》。本次回购股份用于员工持股计划或股权激励，回购期限为2026年6月1日至2027年5月31日，拟回购金额为10,000万元至20,000万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300036130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","BK0239","688506","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640593669","title":"百利天恒(688506.SH)拟1亿元至2亿元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2640593669","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640593669?lang=zh_cn&edition=full","pubTime":"2026-06-01 19:42","pubTimestamp":1780314167,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司拟1亿元至2亿元回购股份，回购价格不超过398元/股，回购的股份将在未来适宜时机全部用于实施员工持股计划或股权激励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02615","BK0239","91194","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640375239","title":"百利天恒跌10.66% 华泰证券喊买入后股价屡跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2640375239","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640375239?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:01","pubTimestamp":1780304468,"startTime":"0","endTime":"0","summary":"中国经济网北京6月1日讯 百利天恒(688506.SH)今日收报213.15元，跌幅10.66%。百利天恒5月25日以来6个交易日中有4个交易日股价下跌。\r\n\r\n 华泰证券股份有限公司研究员代雯、袁中平5月25日发布研报《百利天恒(688506)：ASCO大会多项数据将密集披露》称，维持“买入”。\r\n\r\n (责任编辑：徐自立)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260601/32266270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0012","601688","LU1328615791.USD","BK0028","LU1934453819.USD","BK0239","LU0039217434.USD","02615","LU1064131003.USD","LU0871576103.HKD","LU0164865239.USD","91194","LU1781817850.SGD","LU2148510915.USD","LU1064130708.USD","LU1580142542.USD","BK0276","LU1808992512.USD","LU1979443071.USD","LU0531971595.HKD","688506","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639965628","title":"5月29日百利天恒涨8.64%，中欧医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2639965628","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639965628?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:41","pubTimestamp":1780044062,"startTime":"0","endTime":"0","summary":"证券之星消息，5月29日百利天恒涨8.64%创60日新低，收盘报238.57元，换手率1.21%，成交量5.0万手，成交额11.68亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共128家，其中持有数量最多的公募基金为中欧基金的中欧医疗健康混合A。中欧医疗健康混合A目前规模为129.74亿元，最新净值1.5925，较上一交易日下跌2.4%，近一年下跌1.79%。中欧医疗健康混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900030299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","BK0239","91194","159760","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639628197","title":"百利天恒涨8.64%，开源证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2639628197","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639628197?lang=zh_cn&edition=full","pubTime":"2026-05-29 16:40","pubTimestamp":1780044053,"startTime":"0","endTime":"0","summary":"今日百利天恒涨8.64%，收盘报238.57元。2026年4月29日，开源证券研究员余汝意,聂媛媛发布了对百利天恒的研报《Iza-bren商业化在即，多产品将开展全球注册临床》，该研报对百利天恒给出“买入”评级。研报中预计公司2026-2028年营收为24.76/22.99/30.76，当前股价对应PE分别为47.5/51.5/38.2倍，维持“买入”评级。百利天恒个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900030286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","91194","02615","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638613056","title":"百利天恒跌6.83% 招商证券在历史大顶发研报强烈推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2638613056","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638613056?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:34","pubTimestamp":1779960844,"startTime":"0","endTime":"0","summary":"中国经济网北京5月28日讯 百利天恒(688506.SH)今日收报219.60元，跌幅6.83%。\r\n\r\n 2025年9月8日，百利天恒股价盘中创上市以来高点414.02元。\r\n\r\n 招商证券股份有限公司研究员梁广楷、许菲菲、焦玉鹏2025年9月12日发布研报《百利天恒(688506)：从双抗ADC出发 多平台布局迈向国际领先的MNC》称，给予“强烈推荐”投资评级。\r\n\r\n 国泰海通证券股份有限公司研究员余文心、廖博闻2025年9月12日发布研报《百利天恒(688506)：WCLC上公布全球BIC数据 IZA-BREN有望冲击一线市场》称，维持增持评级。\r\n\r\n (责任编辑：徐自立)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260528/32261611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0012","600999","BK0028","BK0276","02615","06099","BK0183","BK1147","BK0188","BK0239","91194","BK1564","BK0010","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638537856","title":"东吴证券：给予百利天恒买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2638537856","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638537856?lang=zh_cn&edition=full","pubTime":"2026-05-25 19:01","pubTimestamp":1779706876,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广近期对百利天恒进行研究并发布了研究报告《iza-bren领衔亮相，5款新药7项数据登陆ASCO》，给予百利天恒买入评级。我们认为公司以iza-bren为首的平台技术领先，商业化潜力大，研发顺利推进，待公司后续创新产品兑现实现扭亏，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为361.02。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500026911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601555","688506","02615","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637137365","title":"每周股票复盘：百利天恒（688506）2025年净亏损10.54亿元，营收降56.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637137365","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637137365?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:20","pubTimestamp":1779560417,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，百利天恒报收于240.06元，较上周的257.01元下跌6.6%。本周，百利天恒5月21日盘中最高价报261.0元。来自业绩披露要点：2025年营业收入为252,011.33万元，同比下降56.72%。出席会议的股东及代理人共223人，代表有表决权股份总数的80.2594%。中信证券股份有限公司作为保荐人，对四川百利天恒药业股份有限公司2025年度持续督导期间的经营与财务状况进行跟踪。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91194","02615","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637519390","title":"百利天恒跌4% 招商证券在其历史大顶发研报强烈推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2637519390","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637519390?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:22","pubTimestamp":1779441731,"startTime":"0","endTime":"0","summary":"中国经济网北京5月22日讯 百利天恒(688506.SH)今日收报240.06元，跌幅4.01%。\r\n\r\n 2025年9月8日，百利天恒股价盘中创上市以来高点414.02元。\r\n\r\n 招商证券股份有限公司研究员梁广楷、许菲菲、焦玉鹏2025年9月12日发布研报《百利天恒(688506)：从双抗ADC出发 多平台布局迈向国际领先的MNC》称，给予“强烈推荐”投资评级。\r\n\r\n 国泰海通证券股份有限公司研究员余文心、廖博闻2025年9月12日发布研报《百利天恒(688506)：WCLC上公布全球BIC数据 IZA-BREN有望冲击一线市场》称，维持增持评级。\r\n\r\n (责任编辑：徐自立)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260522/32247141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["600999","02615","BK0012","BK0239","688506","BK1147","BK0188","BK0028","BK1564","BK0276","91194","BK0183","BK0010","06099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637332611","title":"百利天恒（688506）发布2025年度持续督导跟踪报告，5月21日股价上涨1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637332611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637332611?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:25","pubTimestamp":1779373518,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，百利天恒报收于250.1元，较前一交易日上涨1.13%，最新总市值为1032.6亿元。该股当日开盘248.5元，最高261.0元，最低247.92元，成交额达6.36亿元，换手率为0.61%。近日，中信证券股份有限公司发布《关于四川百利天恒药业股份有限公司2025年度持续督导跟踪报告》。公告显示，2025年公司营业收入为252,011.33万元，同比下降56.72%；净利润为-105,361.79万元，由盈转亏。主要因2024年确认大额知识产权授权收入，而2025年该类收入减少，同时研发投入同比增长74.23%至251,372.55万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02615","688506","BK0239","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636944852","title":"百利天恒（688506）披露2025年年度股东会决议公告，5月19日股价下跌2.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636944852","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636944852?lang=zh_cn&edition=full","pubTime":"2026-05-19 22:12","pubTimestamp":1779199945,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，百利天恒报收于247.03元，较前一交易日下跌2.15%，最新总市值为1019.92亿元。该股当日开盘256.97元，最高256.97元，最低244.88元，成交额达3.93亿元，换手率为0.38%。近日，四川百利天恒药业股份有限公司披露《2025年年度股东会决议公告》。公告显示，公司于2026年5月19日召开2025年年度股东会，会议由董事长朱义主持，采用现场与网络投票相结合方式召开。出席会议的股东及代理人共223人，代表有表决权股份总数的80.2594%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900043520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688506","91194","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635379062","title":"百利天恒(688506.SH)：SI-B036双特异性抗体注射液获批在晚期实体瘤中开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2635379062","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635379062?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:21","pubTimestamp":1778750492,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)公告，公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》，公司自主研发的创新生物药SI-B036双特异性抗体注射液的药物临床试验获得批准，同意该品单药在晚期实体瘤中开展临床试验。据悉，SI-B036双特异性抗体注射液是公司自主研发的全球领先的特异性增强双特异性抗体平台(SEBA平台)的产品之一，SEBA分子不仅可以提高靶向性和抗肿瘤活性，还可以最大限度地减少脱靶效应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","91194","02615","SI","BK4211","688506","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635783831","title":"百利天恒（688506）披露2025年年度股东会会议资料，5月13日股价上涨0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635783831","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635783831?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:20","pubTimestamp":1778667610,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，百利天恒报收于264.6元，较前一交易日上涨0.57%，最新总市值为1092.46亿元。公司于近日披露《四川百利天恒药业股份有限公司2025年年度股东会会议资料》。公告显示，四川百利天恒药业股份有限公司召开2025年年度股东会，审议2025年度董事会工作报告、利润分配方案、年度报告及其摘要、2026年度董事薪酬、续聘会计师事务所、担保额度预计及董事及高级管理人员薪酬管理制度等议案，并听取独立董事述职报告和高级管理人员薪酬方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300034335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688506","BK0239","02615","91194"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221419","title":"恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221419","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635221419?lang=zh_cn&edition=full","pubTime":"2026-05-13 08:02","pubTimestamp":1778630577,"startTime":"0","endTime":"0","summary":"政策动向国家药监局局长黄果会见新加坡卫生科学局局长蔡瑞文双方就创新医疗器械等议题深入交换意见国家药监局局长黄果5月11日在京会见了来访的新加坡卫生科学局局长蔡瑞文一行，并签署《中华人民共和国国家药品监督管理局与新加坡共和国卫生科学局监管合作谅解备忘录》。双方就细胞和基因治疗、创新医疗器械及人工智能产品监管等议题深入交换意见。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605133735150673.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735150673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","LU1066051225.USD","LU2289578879.USD","LU2461242641.AUD","LU2097828557.USD","LU1983299246.USD","LU0648001328.SGD","BK0028","LU1023057109.AUD","LU0359202008.SGD","LU2097828805.USD","BK4516","LU0405327148.USD","LU1069347547.HKD","LU2360032135.SGD","SG9999014559.SGD","LU1989771016.USD","LU2023250504.SGD","LU2125154935.USD","LU0477156953.USD","BK4550","LU0985320562.USD","SG9999002224.SGD","LU2106854487.HKD","LU1989772840.SGD","LU1699723380.USD","IE00BJJMRZ35.SGD","LU1974910355.USD","LU2089984988.USD","SG9999015358.SGD","IE000M9KFDE8.USD","01276","LU0130102774.USD","BK4007","BK4533","LU1291159041.SGD","688506","IE0009355771.USD","LU2488822045.USD","IE00BJT1NW94.SGD","LU1035773651.USD","MRK","LU1929549753.HKD","LU0965509283.SGD","SG9999001176.SGD","LU2361045086.USD","LU1037948541.HKD","IE00B1BXHZ80.USD","LU2357627491.SGD","BK0012","IE00BSNM7G36.USD","LU0130517989.USD","LU2097828474.EUR","LU0965509010.AUD","002022","BK0188","LU0289739699.SGD","SG9999001440.SGD","LU1934455863.HKD","LU2112291526.USD","BK0196","BK4559","LU1580142542.USD","BK1191","LU1430594728.SGD","BK0183","LU2324357040.USD","LU0122379950.USD","LU1997245094.SGD","LU0868494708.USD","LU0432979614.USD","600276","LU1146622755.USD","LU0405327494.USD","BK4534","LU2495084118.USD","LU1934455194.USD","LU1571399168.USD","LU0359201885.HKD","LU0203345920.USD","LU2491050071.SGD","LU0265550359.USD","LU1997244956.HKD","LU2148510915.USD","LU2361044865.SGD","LU1066051498.USD","IE00BBT3K403.USD","BK0239","301206","LU0106261372.USD","LU0861579265.USD","LU1037948897.HKD","LU2125154778.USD","LU1057294990.SGD","LU0320765489.SGD","LU0006306889.USD","LU1934455277.USD","LU2580892789.USD","SG9999014542.SGD","LU2328871848.SGD","LU1066053197.SGD","IE00BLSP4452.SGD","LU1585245621.USD","LU0965509101.SGD","IE00BLSP4239.USD","SG9999013999.USD","LU1061106388.HKD","LU1820825898.SGD","LU0965508806.USD","LU2097828714.EUR","SGXZ57979304.SGD","LU1969619763.USD","BK4585","SG9999002232.USD","LU1781817850.SGD","LU2491050154.USD","LU1116320737.USD","SG9999015341.SGD","LU0266013472.USD","LU1116320901.HKD","LU1064130708.USD","IE00BN8TJ469.HKD","LU0234572021.USD","LU2543165471.USD","LU2468319806.SGD","LU2491049909.HKD","SG9999014567.USD","BK4588","LU1093756168.USD","IE00B4R5TH58.HKD","LU0238689110.USD","SG9999014575.USD","LU0203347892.USD","LU0211331839.USD","LU0265550946.USD","LU1066051811.HKD","LU1655091616.SGD","LU2097828631.EUR","SG9999001176.USD","IE00BFTCPJ56.SGD","LU0942090050.USD","LU0980610538.SGD","LU1255011170.USD","IE00B2B36J28.USD","LU1989772923.USD","LU1023059063.AUD","LU0859254822.USD","LU1162221912.USD","LU1328615791.USD","LU1093756325.SGD","LU1997245177.USD","LU0359201612.USD","LU1201861249.SGD","LU1941712348.USD","LU0320765646.SGD","LU2023250843.SGD","LU0058720904.USD","LU1941712264.USD","BK0060","LU0208291251.USD","LU2580892862.HKD","LU2361044949.HKD","LU1917777945.USD","LU0070302665.USD","IE0002141913.USD","LU0098860793.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634292337","title":"百利天恒董秘空缺超三个月 董事长暂代职","url":"https://stock-news.laohu8.com/highlight/detail?id=2634292337","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634292337?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:35","pubTimestamp":1778578500,"startTime":"0","endTime":"0","summary":"5月12日，百利天恒（688506）发布公告，因董事会秘书陈英格因个人原因辞职，现由公司董事、高级管理人员张苏娅代行董事会秘书职责。张苏娅代行职责已满三个月，因公司尚未完成董事会秘书的聘任工作，自2026年5月13日起，公司法定代表人、董事长、总经理朱义代行董事会秘书职责，直至新董事会秘书聘任完成。公司将尽快完成董事会秘书的聘任工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734572276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["91194","BK0239","02615","688506"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634529442","title":"百利天恒最新公告：注射用T-Bren用于一线HER2阳性乳腺癌III期临床试验完成首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2634529442","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634529442?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:28","pubTimestamp":1778578101,"startTime":"0","endTime":"0","summary":"百利天恒(688506.SH)公告称，公司自主研发的创新生物药注射用T-Bren(HER2ADC)联合帕妥珠单抗和曲妥珠单抗对比帕妥珠单抗联合多西他赛用于一线HER2阳性的复发或转移性乳腺癌III期临床试验已完成首例受试者入组。截至目前，T-Bren正在国内外开展17项临床试验，覆盖乳腺癌、胃癌、非小细胞肺癌等多种适应症。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200029763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91194","688506","02615"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634629466","title":"百利天恒：iza-bren（EGFR×HER3双抗ADC）获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2634629466","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634629466?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:18","pubTimestamp":1778577480,"startTime":"0","endTime":"0","summary":"南财智讯5月12日电，百利天恒公告，iza-bren（EGFR×HER3双抗ADC）收到国家药品监督管理局《药物临床试验批准通知书》（通知书编号：2026LP01442），同意该药开展联合小分子靶向药物用于治疗驱动基因阳性的局部晚期或转移性非小细胞肺癌的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734555430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688506","BK4080","91194","BK0239","02615","BK4231","ADC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780577942104,"stockEarnings":[{"period":"1week","weight":-0.1},{"period":"1month","weight":-0.2222},{"period":"3month","weight":-0.1677},{"period":"6month","weight":-0.4171},{"period":"1year","weight":-0.2749},{"period":"ytd","weight":-0.3435}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0069},{"period":"3month","weight":-0.006},{"period":"6month","weight":0.0464},{"period":"1year","weight":0.2148},{"period":"ytd","weight":0.029}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川百利天恒药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7777人(较上一季度增加34.99%)","perCapita":"53089股","listingDate":"2023-01-06","address":"四川省成都市温江区成都海峡两岸科技产业园百利路161号一幢一号","registeredCapital":"41287万元","survey":" 四川百利天恒药业股份有限公司的主营业务是创新生物药业务和化药制剂、中成药制剂业务。公司的主要产品是知识产权收入、化药制剂、中成药制剂。","listedPrice":24.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百利天恒,688506,百利天恒股票,百利天恒股票老虎,百利天恒股票老虎国际,百利天恒行情,百利天恒股票行情,百利天恒股价,百利天恒股市,百利天恒股票价格,百利天恒股票交易,百利天恒股票购买,百利天恒股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百利天恒(688506)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百利天恒(688506)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}